BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 10, 2024
See today's BioWorld
Home
» Abbvie protects its nest egg, gives some certainty to Humira biosimilar market
To read the full story,
subscribe
or
sign in
.
Abbvie protects its nest egg, gives some certainty to Humira biosimilar market
April 6, 2018
By
Mari Serebrov
No Comments
Even though Humira's U.S. composition of matter patent expired more than a year ago and biosimilars are waiting to roll out, a basket lined with other patents will continue to protect Abbvie Inc.'s nest egg in the U.S. for a few more years.
BioWorld